Pliant Therapeutics, Inc.
NASDAQ:PLRX
15.19 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 1.58 | 9.685 | 7.572 | 41.817 | 57.052 | 0 | 0 |
| Cost of Revenue
| 1.841 | 3.681 | 3.204 | 0 | 0 | 0.666 | 0 |
| Gross Profit
| -0.261 | 6.004 | 4.368 | 41.817 | 57.052 | -0.666 | 0 |
| Gross Profit Ratio
| -0.165 | 0.62 | 0.577 | 1 | 1 | 0 | 0 |
| Reseach & Development Expenses
| 125.956 | 96.936 | 77.549 | 66.193 | 47.353 | 24.415 | 14.526 |
| General & Administrative Expenses
| 57.928 | 39.949 | 27.558 | 17.269 | 10.93 | 6.5 | 3.823 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 57.928 | 39.949 | 27.558 | 17.269 | 10.93 | 6.5 | 3.823 |
| Other Expenses
| 0 | 0 | -77.549 | -0.366 | -0.216 | -0.049 | 0 |
| Operating Expenses
| 183.884 | 136.885 | 27.558 | 83.462 | 58.283 | 30.915 | 18.349 |
| Operating Income
| -184.145 | -127.2 | -19.986 | -41.645 | -1.231 | -30.915 | -18.349 |
| Operating Income Ratio
| -116.547 | -13.134 | -2.639 | -0.996 | -0.022 | 0 | 0 |
| Total Other Income Expenses Net
| 22.809 | 3.879 | 0.272 | 0.112 | 0.6 | -0.049 | 0.016 |
| Income Before Tax
| -161.336 | -123.321 | -19.714 | -41.533 | -0.631 | -30.276 | -18.333 |
| Income Before Tax Ratio
| -102.111 | -12.733 | -2.604 | -0.993 | -0.011 | 0 | 0 |
| Income Tax Expense
| 1.673 | -1.823 | -1.807 | -1.788 | -0.816 | 0.639 | 2.289 |
| Net Income
| -161.336 | -121.498 | -17.907 | -39.745 | 0.185 | -30.276 | -20.622 |
| Net Income Ratio
| -102.111 | -12.545 | -2.365 | -0.95 | 0.003 | 0 | 0 |
| EPS
| -2.75 | -2.89 | -0.5 | -1.12 | 0.005 | -1.83 | -25.67 |
| EPS Diluted
| -2.75 | -2.89 | -0.5 | -1.12 | 0.005 | -1.83 | -25.67 |
| EBITDA
| -182.304 | -122.53 | -19.986 | -41.645 | -0.118 | -30.249 | -18.057 |
| EBITDA Ratio
| -115.382 | -12.652 | -2.639 | -0.996 | -0.002 | 0 | 0 |